Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 and Axitinib in Resectable NSCLC
NCT06020352Phase 3Unknown
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Aug 2023
- Primary completion
- Jul 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of erfonrilimab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: Major Pathological Response and Surgical resection rate. Status: unknown.
02
Drugs
erfonrilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06020352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06020352.